Women Infertility - Pipeline Review, H1 2018 by MarketResearchReports.biz
"The Report Women
Infertility - Pipeline Review, H1 2018 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Women
Infertility
Market
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Women
Infertility - Pipeline Review, H1 2018, provides an overview of the
Women Infertility (Women's Health) pipeline landscape.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1743245
Infertility refers to failure to
conceive over the course of one full year. Women infertility is
caused due to damage of fallopian tubes, ovulation disorders
(polycystic ovary syndrome) and endometriosis. Symptoms include
abnormal periods, weight gain, back pain, pelvic pain, and cramping.
Risk factor of infertility
includes smoking tobacco, using alcohol, being overweight, being
exposed to toxins, certain medical conditions, including tumors and
chronic illnesses. Treatment includes medications to stimulate
ovulation and hormone therapies.
Report Highlights
Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Women Infertility
- Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Women Infertility (Women's
Health), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type.
Request
for TOC @
https://www.marketresearchreports.biz/reports/1743245/women-infertility-pipeline-review-h1-2018-market-research-reports/toc
The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The Women Infertility (Women's
Health) pipeline guide also reviews of key players involved in
therapeutic development for Women Infertility and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II,
Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are
2, 9, 16, 14, 1, 23, 6 and 1 respectively. Similarly, the
Universities portfolio in Phase II, Preclinical and Discovery stages
comprises 2, 5 and 4 molecules, respectively.
Women Infertility (Women's Health)
pipeline guide helps in identifying and tracking emerging players in
the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
The guide is built using data and
information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time
basis.
Note: Certain content / sections
in the pipeline guide may be removed or altered based on the
availability and relevance of data.
Scope
- The pipeline guide provides a
snapshot of the global therapeutic landscape of Women Infertility
(Women's Health).
- The pipeline guide reviews
pipeline therapeutics for Women Infertility (Women's Health) by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
- The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features
descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Women Infertility (Women's Health) therapeutics
and enlists all their major and minor projects.
- The pipeline guide evaluates
Women Infertility (Women's Health) therapeutics based on mechanism of
action (MoA), drug target, route of administration (RoA) and molecule
type.
- The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Women Infertility (Women's Health)
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
- Recognize emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Find and recognize significant
and varied types of therapeutics under development for Women
Infertility (Women's Health).
- Classify potential new clients
or partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures
for pipeline projects by understanding Women Infertility (Women's
Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential
and scope.
- Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
View
Report @
https://www.marketresearchreports.biz/reports/1743245/women-infertility-pipeline-review-h1-2018-market-research-reports
Table of Contents
Table of Contents 2
Introduction 5
Women Infertility - Overview 6
Women Infertility - Therapeutics
Development 7
Women Infertility - Therapeutics
Assessment 17
Women Infertility - Companies
Involved in Therapeutics Development 26
Women Infertility - Drug Profiles
42
Women Infertility - Dormant
Projects 160
Women Infertility - Discontinued
Products 164
Women Infertility - Product
Development Milestones 165
Appendix 173
List of Tables
Number of Products under
Development for Women Infertility, H1 2018
Number of Products under
Development by Companies, H1 2018
Number of Products under
Development by Universities/Institutes, H1 2018
Products under Development by
Companies, H1 2018
Products under Development by
Universities/Institutes, H1 2018
Number of Products by Stage and
Target, H1 2018
Number of Products by Stage and
Mechanism of Action, H1 2018
Number of Products by Stage and
Route of Administration, H1 2018
Number of Products by Stage and
Molecule Type, H1 2018
Women Infertility - Pipeline by 4P
Therapeutics LLC, H1 2018
Women Infertility - Pipeline by
AbbVie Inc, H1 2018
Women Infertility - Pipeline by
Addex Therapeutics Ltd, H1 2018
Women Infertility - Pipeline by
ASKA Pharmaceutical Co Ltd, H1 2018
Women Infertility - Pipeline by
Astellas Pharma Inc, H1 2018
Women Infertility - Pipeline by
Bayer AG, H1 2018
Women Infertility - Pipeline by
Bharat Serums And Vaccines Ltd, H1 2018
Women Infertility - Pipeline by
Cadila Healthcare Ltd, H1 2018
Women Infertility - Pipeline by
Dong-A Socio Holdings Co Ltd, H1 2018
Women Infertility - Pipeline by
ElexoPharm GmbH, H1 2018
Women Infertility - Pipeline by
EndoCeutics Inc, H1 2018
Women Infertility - Pipeline by
Enteris BioPharma Inc, H1 2018
Women Infertility - Pipeline by
Evotec AG, H1 2018
Women Infertility - Pipeline by
Ferring International Center SA, H1 2018
Women Infertility - Pipeline by
Forendo Pharma Ltd, H1 2018
Women Infertility - Pipeline by
Glycotope GmbH, H1 2018
Women Infertility - Pipeline by
Immunitor Inc, H1 2018
Women Infertility - Pipeline by
Isifer AB, H1 2018
Women Infertility - Pipeline by
Kissei Pharmaceutical Co Ltd, H1 2018
Women Infertility - Pipeline by
Livzon Pharmaceutical Group Inc, H1 2018
Women Infertility - Pipeline by
Luye Pharma Group Ltd, H1 2018
Women Infertility - Pipeline by
Myovant Sciences Ltd, H1 2018
Women Infertility - Pipeline by
Navya Biologicals Pvt Ltd, H1 2018
Women Infertility - Pipeline by
Nippon Shinyaku Co Ltd, H1 2018
Women Infertility - Pipeline by
ObsEva SA, H1 2018
Women Infertility - Pipeline by
Ogeda SA, H1 2018
Women Infertility - Pipeline by
Pangen Biotech Inc., H1 2018
Women Infertility - Pipeline by
Philogen SpA, H1 2018
Women Infertility - Pipeline by
Repros Therapeutics Inc, H1 2018
Women Infertility - Pipeline by
Richter Gedeon Nyrt, H1 2018
Women Infertility - Pipeline by SK
Chemicals Co Ltd, H1 2018
Women Infertility - Pipeline by
Takeda Pharmaceutical Co Ltd, H1 2018
Women Infertility - Pipeline by
ValiRx Plc, H1 2018
Women Infertility - Pipeline by
Viramal Ltd, H1 2018
Women Infertility - Dormant
Projects, H1 2018
Women Infertility - Discontinued
Products, H1 2018
List of Figures
Number of Products under
Development for Women Infertility, H1 2018
Number of Products under
Development by Companies, H1 2018
Number of Products under
Development by Universities/Institutes, H1 2018
Number of Products by Top 10
Targets, H1 2018
Number of Products by Stage and
Top 10 Targets, H1 2018
Number of Products by Top 10
Mechanism of Actions, H1 2018
Number of Products by Stage and
Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of
Administration, H1 2018
Number of Products by Stage and
Routes of Administration, H1 2018
Number of Products by Molecule
Types, H1 2018
Number of Products by Stage and
Molecule Types, H1 2018
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment